Knockdown of S100A2 inhibits the aggressiveness of endometrial cancer by activating STING pathway

References

• Bulk, E., et al., 2009. S100A2 induces metastasis in non-small cell lung cancer. Clinical Cancer Research, 15 (1), 1–8.
   PubMed Web of Science ®Google Scholar
• Chen, Y., et al., 2021. S100A2 is a prognostic biomarker involved in immune infiltration and predict immunotherapy response in pancreatic cancer. Frontiers in Immunology, 12, 758004.
   PubMed Web of Science ®Google Scholar
• Conza, D., et al., 2021. Metformin dysregulates the unfolded protein response and the WNT/beta-catenin pathway in endometrial cancer cells through an AMPK-independent mechanism. Cells, 10 (5), 1067.
   PubMed Web of Science ®Google Scholar
• de Boer, S.M., et al., 2019. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. The Lancet. Oncology, 20 (9), 1273–1285.
   PubMed Web of Science ®Google Scholar
• Dixit, G., et al., 2023. FGFR2 mutations promote endometrial cancer progression through dual engagement of EGFR and Notch signalling pathways. Clinical and Translational Medicine, 13 (5), e1223.
   PubMed Web of Science ®Google Scholar
• Doi, S., et al., 2021. Regulation of the tubulin polymerization-promoting protein by Ca2+/S100 proteins. Cell Calcium, 96, 102404.
   PubMed Web of Science ®Google Scholar
• Gao, Y., Liu, T., and Huang, Y., 2015. MicroRNA-134 suppresses endometrial cancer stem cells by targeting POGLUT1 and Notch pathway proteins. FEBS Letters, 589 (2), 207–214.
   PubMed Web of Science ®Google Scholar
• Kong, C., et al., 2021. Downregulation of HOXA11 enhances endometrial cancer malignancy and cisplatin resistance via activating PTEN/AKT signaling pathway. Clinical & Translational Oncology, 23 (7), 1334–1341.
   PubMed Web of Science ®Google Scholar
• Krishnamurthy, N. and Kurzrock, R., 2018. Targeting the Wnt/beta-catenin pathway in cancer: update on effectors and inhibitors. Cancer Treatment Reviews, 62, 50–60.
   PubMed Web of Science ®Google Scholar
• Kyriazanos, I.D., et al., 2002. Expression and prognostic significance of S100A2 protein in squamous cell carcinoma of the esophagus. Oncology Reports, 9 (3), 503–510.
   PubMed Web of Science ®Google Scholar
• Lapi, E., et al., 2006. S100A2 gene is a direct transcriptional target of p53 homologues during keratinocyte differentiation. Oncogene, 25 (26), 3628–3637.
   PubMed Web of Science ®Google Scholar
• Li, C., et al., 2020. S100A2 promotes glycolysis and proliferation via GLUT1 regulation in colorectal cancer. FASEB Journal, 34 (10), 13333–13344.
   PubMed Web of Science ®Google Scholar
• Liu, Y., et al., 2020. UBE2C is upregulated by estrogen and promotes epithelial–mesenchymal transition via p53 in endometrial cancer. Molecular Cancer Research, 18 (2), 204–215.
   PubMed Web of Science ®Google Scholar
• Naz, S., et al., 2014. Protumorigenic actions of S100A2 involve regulation of PI3/Akt signaling and functional interaction with Smad3. Carcinogenesis, 35 (1), 14–23.
   PubMed Web of Science ®Google Scholar
• Popli, P., et al., 2020. Splicing factor SF3B1 promotes endometrial cancer progression via regulating KSR2 RNA maturation. Cell Death & Disease, 11 (10), 842.
   PubMed Web of Science ®Google Scholar
• Shin, S.Y., et al., 2006. Clozapine, a neuroleptic agent, inhibits Akt by counteracting Ca2+/calmodulin in PTEN-negative U-87MG human glioblastoma cells. Cellular Signalling, 18 (11), 1876–1886.
   PubMed Web of Science ®Google Scholar
• Si, Y., et al., 2023. Phellodendronoside A exerts anticancer effects depending on inducing apoptosis through ROS/Nrf2/Notch pathway and modulating metabolite profiles in hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 10, 935–948.
   PubMed Web of Science ®Google Scholar
• Sugino, H. and Sawada, Y., 2022. Influence of S100A2 in human diseases. Diagnostics, 12 (7), 1756.
   Web of Science ®Google Scholar
• Sugiyama, T., Ozono, S., and Miyake, H., 2020. Expression profile of S100A2 and its clinicopathological significance in renal cell carcinoma. Anticancer Research, 40 (11), 6337–6343.
   PubMed Web of Science ®Google Scholar
• Tossetta, G. and Marzioni, D., 2023. Targeting the NRF2/KEAP1 pathway in cervical and endometrial cancers. European Journal of Pharmacology, 941, 175503.
   PubMed Web of Science ®Google Scholar
• Urick, M.E. and Bell, D.W., 2019. Clinical actionability of molecular targets in endometrial cancer. Nature Reviews Cancer, 19 (9), 510–521.
   PubMed Web of Science ®Google Scholar
• Wang, H., et al., 2021. miR-325-3p promotes the proliferation, invasion, and EMT of breast cancer cells by directly targeting S100A2. Oncology Research, 28 (7), 731–744.
   PubMed Web of Science ®Google Scholar
• Wang, T., Du, G., and Wang, D., 2021. The S100 protein family in lung cancer. Clinica Chimica Acta, 520, 67–70.
   PubMed Web of Science ®Google Scholar
• Wang, T., et al., 2017. Expression and clinicopathological significance of S100 calcium binding protein A2 in lung cancer patients of Chinese Han ethnicity. Clinica Chimica Acta, 464, 118–122.
   PubMed Web of Science ®Google Scholar
• Wang, X. and Chen, T., 2021. CUL4A regulates endometrial cancer cell proliferation, invasion and migration by interacting with CSN6. Molecular Medicine Reports, 23 (1), 23.
   PubMed Web of Science ®Google Scholar
• Yin, A., et al., 2021. Integrative analysis identifies an immune-relevant epigenetic signature for prognostication of non-G-CIMP glioblastomas. Oncoimmunology, 10 (1), 1902071.
   PubMed Web of Science ®Google Scholar
• Zeng, X., et al., 2022. IL6 induces mtDNA leakage to affect the immune escape of endometrial carcinoma via cGAS-STING. Journal of Immunology Research, 2022, 3815853.
   PubMed Web of Science ®Google Scholar
• Zhang, C., et al., 2021. S100 family members: potential therapeutic target in patients with hepatocellular carcinoma: a STROBE study. Medicine, 100 (3), e24135.
   PubMed Web of Science ®Google Scholar
• Zhang, Q., et al., 2022. High expression of S100A2 predicts poor prognosis in patients with endometrial carcinoma. BMC Cancer, 22 (1), 77.
   PubMedGoogle Scholar
• Zhao, Y., Zhang, T., and Wang, Q., 2013. Clinical significance of altered S100A2 expression in gastric cancer. Oncology Reports, 29 (4), 1556–1562.
   PubMed Web of Science ®Google Scholar
• Zheng, S., et al., 2021. Comprehensive analysis of the prognosis and correlations with immune infiltration of S100 protein family members in hepatocellular carcinoma. Frontiers in Genetics, 12, 648156.
   PubMed Web of Science ®Google Scholar
• Zhou, L., et al., 2021. Plasma-derived exosomal miR-15a-5p as a promising diagnostic biomarker for early detection of endometrial carcinoma. Molecular Cancer, 20 (1), 57.
   PubMed Web of Science ®Google Scholar